October 16, 2024, Boston, MA: The AMR Action Fund announced this week that it has invested in TenNor Therapeutics, a clinical stage biotechnology company dedicated to developing new therapies to address unmet needs in infectious diseases. The proceeds will be used to support the development of rifasutenizol, which could become the first new drug developed specifically for Helicobacter pylori infection in more than 30 years.
"The global burden of drug-resistant bacterial infections is staggering and only getting worse, with recent data in The Lancet indicating that nearly 40 million people will die from antimicrobial resistance by 2050," said AMR Action Fund Chief Executive Officer Henry Skinnner, PhD. "We are pleased to support the team at TenNor as they advance the development of novel antibiotics that could save the lives of patients around the world and significantly reduce the suffering associated with these intractable infections."